Home » FDA Orders St. Jude to Conduct Three-Year Review on Riata, Durata and Other Leads

FDA Orders St. Jude to Conduct Three-Year Review on Riata, Durata and Other Leads

August 17, 2012

The FDA ordered St. Jude Medical to launch a three-year postmarket review on its recalled Riata and Riata ST defibrillator leads as well as for its QuickFlex LV CRT, QuickSite LV CRT, Riata ST Optim and Durata leads.
Mass Device

28Sep
The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain
28Sep
Calculating Sample Size to Satisfy FDA Expectations
11Oct
GMP Quality Management vSummit 2023: Where Quality Meets Risk
16Oct
MAGI@home Clinical Research Conference 2023
26Oct
FDA in 2024: What to Expect in an Election Year
08Nov
18th Annual FDA Inspections vSummit

FDA Orders St. Jude to Conduct Three-Year Review on Riata, Durata and Other Leads

Upcoming Events

The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain

Calculating Sample Size to Satisfy FDA Expectations

GMP Quality Management vSummit 2023: Where Quality Meets Risk

MAGI@home Clinical Research Conference 2023

FDA in 2024: What to Expect in an Election Year

18th Annual FDA Inspections vSummit

Featured Products

FDA, FTC and DOJ Enforcement of Medical Device Regulations

Using Real-World Evidence in Drug and Device Submissions

Featured Stories

Manufacturing Cost is Key Issue Facing Gene Therapy Products, Marks Says

Artificial Womb Technology Not Yet Ready for Human Trials Adcomm Says

Top Concern for CBER is Marketing of Unapproved Biologics, Says FDA Official

FDA Deems Medline Industries’ Saline Solution Vial Recall as Class 1

The Revised ICH E8: A Guide to New Clinical Trial Requirements